Algirdas Grevys
Overview
Explore the profile of Algirdas Grevys including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life
Mester S, Chan C, Lustig M, Foss S, Jansen J, Leangen Herigstad M, et al.
PNAS Nexus
. 2025 Mar;
4(2):pgaf042.
PMID: 40041621
Most therapeutic antibodies are based on immunoglobulin G (IgG) due to their potent effector functions and long plasma half-life. However, also monomeric IgA has emerged as an attractive candidate for...
2.
Gjolberg T, Frick R, Mester S, Foss S, Grevys A, Hoydahl L, et al.
Commun Biol
. 2022 Aug;
5(1):832.
PMID: 35982144
Antibody-based therapeutics (ABTs) are used to treat a range of diseases. Most ABTs are either full-length IgG1 antibodies or fusions between for instance antigen (Ag)-binding receptor domains and the IgG1...
3.
Grevys A, Frick R, Mester S, Flem-Karlsen K, Nilsen J, Foss S, et al.
iScience
. 2022 Feb;
25(2):103746.
PMID: 35118359
Monoclonal IgG antibodies are the fastest growing class of biologics, but large differences exist in their plasma half-life in humans. Thus, to design IgG antibodies with favorable pharmacokinetics, it is...
4.
Bern M, Nilsen J, Ferrarese M, Sand K, Gjolberg T, Lode H, et al.
Sci Transl Med
. 2020 Oct;
12(565).
PMID: 33055243
Needle-free uptake across mucosal barriers is a preferred route for delivery of biologics, but the efficiency of unassisted transmucosal transport is poor. To make administration and therapy efficient and convenient,...
5.
Azevedo C, Nilsen J, Grevys A, Nunes R, Andersen J, Sarmento B
J Control Release
. 2020 Aug;
327:161-173.
PMID: 32771477
Oral delivery of biopharmaceuticals, as insulin, is hampered by rapid degradation and inefficient absorption in the gastrointestinal tract (GIT). To solve this, a new class of biodegradable poly(lactic-co-glycolic)-poly(ethylene glycol) (PLGA-PEG)...
6.
Hubbard J, Pyzik M, Rath T, Kozicky L, Sand K, Gandhi A, et al.
J Exp Med
. 2020 Jul;
217(10).
PMID: 32658257
IgG immune complexes (ICs) promote autoimmunity through binding fragment crystallizable (Fc) γ-receptors (FcγRs). Of these, the highly prevalent FcγRIIa (CD32a) histidine (H)-131 variant (CD32aH) is strongly linked to human autoimmune...
7.
Nilsen J, Trabjerg E, Grevys A, Azevedo C, Brennan S, Stensland M, et al.
Commun Biol
. 2020 Apr;
3(1):181.
PMID: 32313072
Albumin has an average plasma half-life of three weeks and is thus an attractive carrier to improve the pharmacokinetics of fused therapeutics. The half-life is regulated by FcRn, a cellular...
8.
Lau C, McAdam M, Bergseth G, Grevys A, Bruun J, Ludviksen J, et al.
MAbs
. 2019 Nov;
12(1):1686319.
PMID: 31671278
The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement...
9.
Shaw A, Hoffecker I, Smyrlaki I, Rosa J, Grevys A, Bratlie D, et al.
Nat Nanotechnol
. 2019 Feb;
14(4):398.
PMID: 30783200
In the Supplementary Information file originally published with this Article, the Supplementary references 48-62 were missing; the amended file has now been uploaded.
10.
Shaw A, Hoffecker I, Smyrlaki I, Rosa J, Grevys A, Bratlie D, et al.
Nat Nanotechnol
. 2019 Jan;
14(2):184-190.
PMID: 30643273
Although repetitive patterns of antigens are crucial for certain immune responses, an understanding of how antibodies bind and dynamically interact with various spatial arrangements of molecules is lacking. Hence, we...